Article
Dexmedetomidine is a safe and useful palliative sedative for refractory dyspnoea in patients with terminal-stage cancer
2022-12-14
Abstract excerpt
<h4>Background: </h4> Dyspnoea affects a considerable percentage of patients with terminal-stage cancer, and clinical guidelines recommend palliative sedation for patients with refractory dyspnoea, which cannot be alleviated with current therapies. Midazolam is currently the most commonly used sedative; however, it can cause serious adverse reactions, such as respiratory/circulatory depression. Hence, there is a n...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- cb71ed3f-71ae-5f67-b271-b9053dd61f93
- DOI
- 10.21203/rs.3.rs-2362027/v1
